EClinicalMedicine · 2020 · 73 citations · 19 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyInfectious Disease PharmacotherapyAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyClinicaltrials.gov RegistrationCombination Therapy EvaluationPlacebo-controlled Efficacy AssessmentRandomizationTreatment Of Coronavirus Infections
BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.). FINDINGS: = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. INTERPRETATION: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19. FUNDING: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar).
19
Philippe Gautret, Jean‐Christophe Lagier, Philippe Parola et al. · International Journal of Antimicrobial Agents · 2020 · 5K citations · Full text
Temporal dynamics in viral shedding and transmissibility of COVID-19
Xi He, Eric H. Y. Lau, Peng Wu et al. · Nature Medicine · 2020 · 4.7K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17
Xueting Yao, Fei Ye, Miao Zhang et al. · Clinical Infectious Diseases · 2020 · 2.8K citations · Full text